HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

5'-Guanylic Acid (GMP)

Subscribe to New Research on 5'-Guanylic Acid

Guanosine 5'-monophosphate. A guanine nucleotide containing one phosphate group esterified to the sugar moiety and found widely in nature.

Also Known As:

GMP; Guanosine Monophosphate; 5' Guanylic Acid; 5'-GMP; Guanylic Acids; 5'-Monophosphate, Guanosine; Acid, 5'-Guanylic; Acids, Guanylic; Guanosine 5' Monophosphate; Monophosphate, Guanosine; Guanosine 5'-Monophosphate; 5'-Guanylic acid

Networked: 855 relevant articles (40 outcomes, 112 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Szabó, Gábor: 7 articles (10/2015 - 06/2009)
2.	Radovits, Tamás: 6 articles (10/2015 - 06/2009)
3.	Souza, Diogo O: 5 articles (10/2008 - 06/2002)
4.	Karck, Matthias: 4 articles (10/2015 - 06/2009)
5.	Stasch, Johannes-Peter: 4 articles (04/2015 - 02/2011)
6.	Nagy, Janice A: 4 articles (10/2012 - 08/2006)
7.	Dvorak, Harold F: 4 articles (10/2012 - 08/2006)
8.	Schmidt, André P: 4 articles (10/2008 - 04/2004)
9.	Olesen, J: 4 articles (05/2008 - 07/2004)
10.	Hirschberg, Kristóf: 3 articles (10/2015 - 06/2009)

Related Diseases

1.	Erectile Dysfunction 09/01/2006 - "Phosphodiesterase type 5 inhibitor drugs produce vasodilatation by inhibiting the breakdown of cyclic guanosine monophosphate and have proven efficacy in treating erectile dysfunction (ED). " 12/01/2009 - "Platelet cyclic guanosine monophosphate as a biomarker of phosphodiesterase type 5 inhibitor efficacy in the treatment of erectile dysfunction: a randomized placebo-controlled study." 05/01/2015 - "Cyclic guanosine monophosphate (cGMP) specific phosphodiesterase type-5 (PDE5), a clinically proven target to treat erectile dysfunction and diseases associated with lower cGMP levels in humans, is present in corpus cavernosum, heart, lung, platelets, prostate, urethra, bladder, liver, brain, and stomach. " 04/01/2010 - "Erectile dysfunction (ED) is a sexual disorder mainly caused by decrease in cellular concentration of cyclic guanosine monophosphate (cGMP), which is degraded by phosphodiesterase type-5 (PDE-5). " 03/01/2009 - "Effect of LDL modified by myeloperoxidase-H2O2-Cl(-) system on intracellular cyclic guanosine monophosphate level of endothelial cells: a link to erectile dysfunction?"
2.	Pain (Aches) 01/01/2000 - "However, the roles of effectors for cyclic guanosine monophosphate are not fully understood in the processing of pain in the spinal cord. " 01/01/2013 - "Pain from self reported gout flares, measured on a 10-point Likert scale, improved more in the SMP/GMP/G600 group compared to controls (MD -1.03, 95% CI -1.96 to -0.10), an absolute difference of 10% (absolute risk difference -0.10, 95% CI -0.20 to -0.01). " 11/01/2013 - "Contrary to some previously studied pain models, the NO/cyclic guanosine monophosphate (cGMP) pathway had no role in thermal hyperalgesia in our study. " 06/01/2012 - "Following treatment with SMP/GMP/G600 over the 3-month period, greater improvements were also observed in pain and fractional excretion of uric acid, with trends to greater improvement in tender joint count. " 10/09/2008 - "The aim of this study was to investigate the effects of intracerebroventricular (i.c.v.) guanosine and GMP on mice pain models. "
3.	Gout 06/01/2012 - "This is the first reported controlled trial of dietary intervention in patients with gout, and suggests that SMP enriched with GMP and G600 may reduce the frequency of gout flares." 06/01/2012 - "The aim of this proof-of-concept clinical trial was to test the hypothesis that daily intake of skim milk powder (SMP) enriched with GMP and G600 can prevent gout flares. " 01/01/2013 - "Pain from self reported gout flares, measured on a 10-point Likert scale, improved more in the SMP/GMP/G600 group compared to controls (MD -1.03, 95% CI -1.96 to -0.10), an absolute difference of 10% (absolute risk difference -0.10, 95% CI -0.20 to -0.01). " 06/01/2012 - "Over the 3-month study period there was a significantly greater reduction in gout flares in the SMP/GMP/G600 group (analysis of covariance p(group)=0.031, Tukey post hoc test compared with lactose control, p=0.044). " 06/01/2012 - "Previous laboratory studies have identified two dairy fractions, glycomacropeptide (GMP) and G600 milk fat extract (G600), with anti-inflammatory effects in models of acute gout. "
4.	Neoplasms (Cancer) 12/01/2014 - "These new conditions will be translated into a GMP protocol in preparation of a clinical adoptive therapy trial to treat patients with MAGE-C2-positive tumors." 10/01/2013 - "The GMP protocols for selection of T(N) and T(CM) we reported here will be the basis for clinical trials analyzing safety, in vivo persistence and clinical efficacy in cancer patients and will help to generate a more reliable and efficacious cellular product." 04/12/2012 - "Elevated intracellular levels of cyclic guanosine monophosphate (cGMP) may induce apoptosis, and at least some cancer cells seem to escape this effect by increased efflux of cGMP, as clinical studies have shown that extracellular cGMP levels are elevated in various types of cancer. " 08/01/2011 - "Although COX inhibition is responsible for the anti-inflammatory activity of SS, recent studies suggest that phosphodiesterase (PDE) 5 inhibition and activation of cyclic guanosine monophosphate (cGMP) signaling are closely associated with its ability to induce apoptosis of tumor cells. " 04/01/2010 - "The goal of the current study was to examine the three constructs from the generic model of psychotherapy (GMP): therapeutic alliance, therapeutic realizations, and therapeutic openness/involvement in the treatment outcome of women with gynecological cancers attending either a 7-session supportive counseling intervention or a coping and communication skills intervention. "
5.	Heart Failure 12/01/1993 - "This study evaluated the relation between plasma cyclic guanosine monophosphate (cGMP) and hemodynamic and neurohormonal parameters in patients with chronic congestive heart failure and assessed the effect of organic nitrate on plasma cGMP levels. " 01/01/2015 - "In the present work, we report the fully compliant GMP-grade production of ATMP-CD133 which aims to address the treatment of chronic refractory ischemic heart failure. " 08/11/2009 - "We sought to identify factors that discriminate heart failure (HF) patients with normal and elevated pulmonary vascular resistance (PVR) and to elucidate the role of cyclic guanosine monophosphate (cGMP)-dependent vasodilation. " 04/01/2004 - "We have demonstrated that acute subcutaneous (SQ) administration of BNP in experimental congestive heart failure results in elevation of plasma BNP and its second messenger 3',5'-cyclic guanosine monophosphate (cGMP) with natriuresis and reduction in cardiac filling pressures. " 09/01/2000 - "Impaired endothelium-dependent, flow-mediated vasodilation in patients with heart failure is partly attributable to hyporesponsiveness of cyclic guanosine monophosphate (cGMP) mediated vasorelaxation effector mechanisms in vascular smooth muscle. "

Related Drugs and Biologics

1.	Nitric Oxide (Nitrogen Monoxide)
2.	5'-Guanylic Acid (GMP)
3.	sildenafil (Viagra)
4.	Adenosine Monophosphate (AMP)
5.	Type 5 Cyclic Nucleotide Phosphodiesterases
6.	Small Interfering RNA (siRNA)
7.	Guanylate Cyclase (Guanylyl Cyclase)
8.	Antigens
9.	Insulin (Novolin)
10.	Heparin (Liquaemin)

Related Therapies and Procedures

1.	Immunotherapy
2.	Drug Therapy (Chemotherapy)
3.	Transplants (Transplant)
4.	Intravenous Infusions
5.	Oral Administration